-
公开(公告)号：US08748490B2
公开(公告)日：2014-06-10
申请号：US13745496
申请日：2013-01-18
Applicant: Edwards Lifesciences Corporation
Inventor： Jeffrey S. Dove , Darin P. Dobler , James A. Davidson , Gregory A. Wright
IPC: A61F2/00
CPC classification number: A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
Abstract translation: 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
公开(公告)号：US20130134064A1
公开(公告)日：2013-05-30
申请号：US13745496
申请日：2013-01-18
Applicant: Edwards Lifesciences Corporation
Inventor： Jeffrey S. Dove , Darin P. Dobler , James A. Davidson , Gregory A. Wright
IPC: A61L27/36
CPC classification number: A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
Abstract translation: 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
公开(公告)号：US10702383B2
公开(公告)日：2020-07-07
申请号：US15990332
申请日：2018-05-25
Applicant: Edwards Lifesciences Corporation
Inventor： Hengchu Cao , Brian S. Conklin , Paul A. Schmidt , Grace M. Kim , James A. Davidson , Hoa T. Tran , Kristy L. Tam
IPC: A61F2/24
Abstract: Disclosed prosthetic valves can comprise a sewing ring configured to secure the valve to an implantation site. Some disclosed valves comprise a resiliently collapsible frame having a neutral configuration and a collapsed deployment configuration. Some disclosed frames can self-expand to the neutral configuration when released from the collapsed deployment configuration. Collapsing a disclosed valve can provide convenient access to the sewing ring, such as for securing the valve to the implantation site, as well as for the insertion of the valve through relatively small surgical incisions.
-
公开(公告)号：US20200038554A1
公开(公告)日：2020-02-06
申请号：US16595089
申请日：2019-10-07
Applicant: Edwards Lifesciences Corporation
Inventor： James A. Davidson , Jeffrey S. Dove , Darin P. Dobler
Abstract: A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.
-
公开(公告)号：US20190262132A1
公开(公告)日：2019-08-29
申请号：US16406862
申请日：2019-05-08
Applicant: Edwards Lifesciences Corporation
Inventor： Bin Tian , James A. Davidson
Abstract: A method of treating a biological tissue that enables dry storage of said tissue is disclosed. In one embodiment, the method comprises contacting the biological tissue with a non-aqueous treatment solution comprising a polyhydric alcohol and a C1-C3 alcohol and removing a portion of the treatment solution from the solution-treated biological tissue. Also disclosed is biological tissue prepared using the above process and prosthetic devices made with such tissue.
-
Patent Agency Ranking
公开(公告)号：US09980816B2
公开(公告)日：2018-05-29
申请号：US14663101
申请日：2015-03-19
Applicant: Edwards Lifesciences Corporation
Inventor： Hengchu Cao , Brian S. Conklin , Paul A. Schmidt , Grace M. Kim , James A. Davidson , Hoa T. Tran , Kristy L. Tam
IPC: A61F2/24
CPC classification number: A61F2/2427 , A61F2/2409 , A61F2/2412 , A61F2/2415
Abstract: Disclosed prosthetic valves can comprise a sewing ring configured to secure the valve to an implantation site. Some disclosed valves comprise a resiliently collapsible frame having a neutral configuration and a collapsed deployment configuration. Some disclosed frames can self-expand to the neutral configuration when released from the collapsed deployment configuration. Collapsing a disclosed valve can provide convenient access to the sewing ring, such as for securing the valve to the implantation site, as well as for the insertion of the valve through relatively small surgical incisions. Examples of delivery systems and methods for deploying the valves exhibit reduced patient trauma.
-
公开(公告)号：US09878068B2
公开(公告)日：2018-01-30
申请号：US14797449
申请日：2015-07-13
Applicant: Edwards Lifesciences Corporation
Inventor： James A. Davidson , Jeffrey S. Dove , Darin P. Dobler
CPC classification number: A61L27/3625 , A61F2/2412 , A61F2210/0004 , A61F2210/0076 , A61L27/3683 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20 , A61L2430/40
Abstract: A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.
-
公开(公告)号：US20150238659A1
公开(公告)日：2015-08-27
申请号：US14707970
申请日：2015-05-08
Applicant: Edwards Lifesciences Corporation
Inventor： Jeffrey S. Dove , Darin P. Dobler , James A. Davidson , Gregory A. Wright
CPC classification number: A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
Abstract translation: 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
公开(公告)号：US20150230922A1
公开(公告)日：2015-08-20
申请号：US14663101
申请日：2015-03-19
Applicant: Edwards Lifesciences Corporation
Inventor： Hengchu Cao , Brian S. Conklin , Paul A. Schmidt , Grace M. Kim , James A. Davidson , Hoa T. Tran , Kristy L. Tam
IPC: A61F2/24
CPC classification number: A61F2/2427 , A61F2/2409 , A61F2/2412 , A61F2/2415
Abstract: Disclosed prosthetic valves can comprise a sewing ring configured to secure the valve to an implantation site. Some disclosed valves comprise a resiliently collapsible frame having a neutral configuration and a collapsed deployment configuration. Some disclosed frames can self-expand to the neutral configuration when released from the collapsed deployment configuration. Collapsing a disclosed valve can provide convenient access to the sewing ring, such as for securing the valve to the implantation site, as well as for the insertion of the valve through relatively small surgical incisions. Examples of delivery systems and methods for deploying the valves exhibit reduced patient trauma.
Abstract translation: 公开的假体瓣膜可以包括构造成将瓣膜固定到植入部位的缝合环。 一些公开的阀包括具有中性构型和折叠展开构型的弹性可折叠框架。 当从折叠部署配置释放时，一些公开的框架可以自扩展到中立配置。 折叠所公开的阀可以方便地进入缝合环，例如用于将瓣膜固定到植入部位，以及通过相对较小的手术切口插入瓣膜。 用于部署阀的递送系统和方法的示例表现出减少的患者创伤。
-
公开(公告)号：US20140200659A1
公开(公告)日：2014-07-17
申请号：US14139367
申请日：2013-12-23
Applicant: Edwards Lifesciences Corporation
Inventor： Jeffrey S. Dove , Darin P. Dobler , James A. Davidson , Gregory A. Wright
CPC classification number: A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
Abstract translation: 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.022 seconds)
